TipRanks
Advertisement
Advertisement

IT:1VRTX Stock Latest News

Vertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
The FlyVertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
12h ago
VRTX
Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan
PremiumThe Fly
Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan
5d ago
VRTX
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
PremiumThe Fly
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
13d ago
ARCT
VRTX
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
PremiumThe Fly
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
14d ago
VRTX
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals
PremiumThe Fly
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals
14d ago
CRNX
VRTX
Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs
PremiumThe FlyVertex Pharmaceuticals added to US Conviction List at Goldman Sachs
15d ago
VRTX
Argenx price target raised to $1,250 from $1,230 at Morgan Stanley
Premium
The Fly
Argenx price target raised to $1,250 from $1,230 at Morgan Stanley
15d ago
ARGX
VRTX
Private Markets: $1B for Base Power, $545M for Whatnot
Premium
The Fly
Private Markets: $1B for Base Power, $545M for Whatnot
26d ago
U
GD
Private Markets: Databricks secures $5B as Kalshi targets $40B valuation
PremiumThe Fly
Private Markets: Databricks secures $5B as Kalshi targets $40B valuation
30d ago
AI
IBM
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
PremiumRatings
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
1M ago
VRTX
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
PremiumThe Fly
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
1M ago
VRTX
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
PremiumThe Fly
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
1M ago
SION
VRTX
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
PremiumThe FlyVertex Pharmaceuticals price target raised to $672 from $605 at BofA
1M ago
SION
VRTX
Early notable gainers among liquid option names on August 10th
Premium
The Fly
Early notable gainers among liquid option names on August 10th
1M ago
APA
AKAM
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
Premium
The Fly
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
1M ago
VRTX
Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays
1M ago
VRTX
Vertex Pharmaceuticals Ups 2026 Outlook Amid Heavy Investment
PremiumCompany Announcements
Vertex Pharmaceuticals Ups 2026 Outlook Amid Heavy Investment
1M ago
VRTX
Vertex: Strong Q2 Beat and Raised Revenue Outlook Underpin Buy Rating and Broadening Growth Beyond CF
PremiumRatings
Vertex: Strong Q2 Beat and Raised Revenue Outlook Underpin Buy Rating and Broadening Growth Beyond CF
1M ago
VRTX
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
PremiumRatings
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
1M ago
VRTX
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
PremiumRatingsVertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
1M ago
VRTX
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
Premium
Ratings
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
1M ago
VRTX
Vertex Upgraded to Buy as Strong Q2, Raised 2026 Guidance and Higher $605 Price Target Signal Durable, Diversified Growth
Premium
Ratings
Vertex Upgraded to Buy as Strong Q2, Raised 2026 Guidance and Higher $605 Price Target Signal Durable, Diversified Growth
1M ago
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >